Heng Pharmaceutical-B (02256.HK) Presents Novel Combination Modelling Framework for ABSK-011 at PAGE Conference

NewTimeSpace News: On June 4, 2026, Heng Pharmaceutical-B (02256.HK) issued a voluntary announcement. The Company delivered two poster presentations covering cutting-edge progress of model-based drug development at the European Population Approach Group in Europe (PAGE) Conference hosted in Dubrovnik, Croatia from June 2 to 5, 2026. One poster introduced an innovative combined modelling framework to predict progression-free survival (PFS) of ABSK-011 (epagratinib) in late-stage FGF19-positive hepatocellular carcinoma patients.

Separately, together with external collaborators, the firm presented a population pharmacokinetic (PopPK) modelling analysis of ABSK-011 developed with Maspectra, a domestically self-developed modelling software, alongside benchmark comparison against NONMEM.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.